Ubiquitinylated proteins

Authors

Christopher Twitty
Erik LeShane
Bernard A Fox, Chiles Research Institute Providence Portland Medical CenterFollow
Hong-Ming Hu, Laboratory of Cancer Immunobiology, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR, USA.Follow
Guangjie Yu, Providence Portland Medical Center, Portland, Oregon, OR, USAFollow

Document Type

Patent

Publication Date

10-10-2014

Abstract

A method of inducing a specific immune response in a mammal, comprising: providing a first composition comprising isolated ubiquitinylated proteins in solution in the absence of membrane bound organelles, the isolated ubiquitinylated proteins comprising one or more specific antigens, and further comprising a threshold quantity of polyubiquitinylated short-lived proteins and polyubiquitinylated defective ribosomal products. The isolated ubiquitinylated proteins are affinity-purified from tumor-derived cells grown in culture, the tumor-derived cells being inhibited from degrading ubiquitinylated proteins via the proteasome while being grown in culture. In this way, highly immunogenic short-lived proteins and defective ribosomal products may be loaded onto dendritic cells for cross-presentation and priming of antigen-specific T cells restricted by either classical or non-classical MHC.

Clinical Institute

Cancer

Specialty/Research Institute

Oncology

Specialty/Research Institute

Earle A. Chiles Research Institute

Location

United States

Comments

Patent Number: 10,226,518

Assignee

UbiVac, LLC (Portland, OR); Providence Health & Science--Oregon (Portland, OR)

Family ID

52809877

Serial Number

14/512,322

Tech ID

13-01-INV